DHEAUSA.COM


Français


English


Русский


Español


Português


Deutsch


Italiano


Swedish


Dutch


日本語
 
 
Merchant Services

     
 

Home

 
 

Contact

 
 

Terms & Conditions

 
 

- - -  Products  - - -

 
 

DHEA

 
 

Melatonin

 
 

Symbiotropin

 
 

Meditropin

 
 

Testron SX

 
 

ProDHEA Cream

 
 

Melatonine Cream

 
 

ProGen Cream

 
 

Glucosamine

 
 

-  Information  -

 
 

Benefits of DHEA

 
 

Products Quality

 
 

DHEA History

 
 

Melatonin Update

 
 

Customers Comments

 
 

Medical Testimonials

 
     

 

Crohn's Disease and DHEA

 

Dehydroepiandrosterone (DHEA) is low in patients with Crohn's Disease. Initial research reports that DHEA supplements are safe for short-term use in patients with Crohn's disease. Preliminary research suggests possible beneficial effects.

Crohn’s Disease is a chronic disorder that causes inflammation of the digestive or gastrointestinal tract. It generally occurs in the lower part of the small intestine, but may affect any part of the digestive tract - from the mouth to the anus.

Crohn’s Disease is also known as Inflammatory Bowel Disease (IBD). This is the general name for diseases that cause inflammation in the intestines.

 

Clinical Studies

  • In a study of 115 Crohn's Disease patients compared to 66 healthy controls and 64 UC patients, both Crohn's Disease and Ulcerative Colitis patients had low serum DHEA-sulfate (DHEAS) levels compared to controls. In Crohn's Disease patients, but not Ulcerative Colitis patients, low DHEAS levels were correlated with high ESR, while high cortisol was associated with high ESR and CRP. Another study found a shift in the ratio of cortisol:DHEA in Crohn's Disease patients with active disease, with higher cortisol and lower DHEA levels.
     

  • A phase 2 pilot trial was conducted to evaluate its effect in IBD patients. Twenty patients (seven with Crohn's Disease; 13 with Ulcerative Colitis), ages 18-45, were given 200 mg Dehydroepiandrosterone orally once daily for 56 days. All patients were experiencing active disease, defined as CDAI > 150, refractory to other medications. All medications remained the same for two weeks prior to and during the study. One patient with Crohn's Disease (and four with Ulcerative Colitis) dropped out because of disease exacerbation or noncompliance. In the Crohn's Disease group, six of seven responded to treatment with a decrease in CDAI of 70 points or more. In all six responders, the CDAI dropped below 150, putting them into remission. The one patient who did not respond dropped out during the first week. Number of liquid stools, bloody diarrhea, abdominal pain, and CRP all decreased. One Crohn's Diseas patient relapsed on day 56. Patients were followed for eight weeks after the end of the study and no further Crohn's Disease relapses were reported.

 

 

 

 

 

 

 

 

 

 




  Copyright 2001- 2017 © DHEAUSA.COM   All rights reserved.